Neoadjuvant BRAF-targeted therapy in regionally advanced and oligometastatic melanoma.

CONCLUSION: Neoadjuvant BRAF-targeted therapy is associated with a high pCR rate in patients with stage III-IV melanoma, which may correlate with improved RFS and OS. This article is protected by copyright. All rights reserved.
PMID: 31329344 [PubMed - as supplied by publisher]

Source: Pigment Cell and Melanoma Research - July 21, 2019 Category: Cytology Authors: Eroglu Z, Eatrides J, Naqvi SMH, Kim Y, Rich J, Babacan NA, Brohl AS, Markowitz J, Sarnaik A, Zager J, Khushalani NI, Sondak VK, Messina J Tags: Pigment Cell Melanoma Res Source Type: research